Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Plume is bringing real-world yield to Solana with the rollout of its Nest vaults, giving the network’s users direct access to ...

Instead of a single, massive LLM, Nvidia's new 'orchestration' paradigm uses a small model to intelligently delegate tasks to ...

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

Two important architectures are Artificial Neural Networks and Long Short-Term Memory networks. LSTM networks are especially ...

Artificial intelligence and machine learning are reshaping how investors build and maintain portfolios. These tools bring ...

Factorial of 100 - The Factorial of Hundred (100!) is one of the most intriguing concepts in mathematics, representing the ...

By building their own intellectual ecosystem, researchers worried about existential AI risk shed academia's baggage — and, ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Paste Magazine is your source for the best music, movies, TV, comedy, videogames, books, comics, craft beer, politics and ...

W hat can sociology tell us about the humanities? Sociological understanding of the humanities began in a field first called ...